Investing.com -- Barclays downgraded Illumina Inc (NASDAQ:ILMN) to "Underweight" given growing uncertainty in China, rising competition from Roche in the clinical market, and weaker-than-expected elasticity in consumables demand.
The firm said these factors raise concerns about management’s ability to meet long-term revenue projections. "we struggle to see how shares would perform with the rest of the group over the rest of the year," analysts wrote in a note.
Barclays (LON:BARC) lowered its price target to $100 from a prior $130. The firm warned that further multiple contraction is possible if China revenues decline materially.
While acknowledging Illumina’s technological edge, Barclays characterized the company as a mature tools business comparable to other genomics and proteomics firms, which typically exhibit mid-single-digit growth and mid-20% operating margins.
Related Articles
Barclays downgrades Illumina on China risks, competition
Amphenol Corp. ratings upgraded to 'A-' by S&P Global on strong business performance
McDonald's international markets prop up sales growth even as US lags
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。